Opus Genetics, Inc. Share Price & Technical Analysis
IRD · $4.26 (-0.70%)
Healthcare / Biotechnology
$4.26
-0.70%
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-16% return in May, -7% avg return in past 3 year May month.
95% return in 2026, -29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | 83% | 12% | 11% | -16% | – | – | – | – | – | – | – | 95% |
| 25 | -8% | -9% | -9% | -10% | 0% | -47% | 22% | 9% | 23% | 44% | -9% | -5% | 1% |
| 24 | -13% | -7% | -23% | -20% | 6% | -12% | 33% | -40% | 8% | -8% | -8% | 9% | -75% |
| 23 | -3% | 0% | 12% | 31% | -26% | 10% | -2% | -7% | -17% | -15% | 7% | -3% | -14% |
| 22 | -14% | 6% | -6% | -26% | -9% | -10% | 0% | 21% | -9% | 15% | 35% | 21% | 25% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$358.08M
P/E ratio
—
52W high
$5.81
52W low
$0.90
Volume
5,64,380
Beta
0.63
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Opus Genetics, Inc. share price today?
- Opus Genetics, Inc. (IRD) last traded around $4.26 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IRD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IRD. Download the app for real-time alerts.
- How can I analyze Opus Genetics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.